An agency review cites new risks of nodules, masses, and numbness and weakness in the face.
Ähnliche Seiten
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indicati...
